Relapsed/refractory HL: FDG-PET is the trump card

Abstract

A number of disease- or host-related markers have been proposed to predict treatment outcome in relapsed/refractory Hodgkin lymphoma (HL). In this issue of Blood, Moskowitz et al demonstrate that fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) performed in sequence during second-line treatment recapitulates all of them.1